Key Development Swiss generic and biosimilar leader Sandoz (SIX: SDZ / OTCQX: SDZNY) has entered into a major commercial licensing... Read more
Global Biosimilar Empire Expansion: Sandoz Signs $322 Million Licensing Deal with Shanghai Henlius for Biosimilar Copies of Repatha®, Benlysta®, and Erbitux®
18/08/2026
Published by Pharma Biz
